• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’

May 5, 2022 By Sean Whooley

Insulet Omnipod 5 Dexcom G6
Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]
Insulet (Nasdaq: PODD) reported first-quarter results that topped the consensus forecast, at the same time that it announced its CEO Shacey Petrovic plans to step down for personal family reasons.

The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022. The results, out this evening, represented a big bottom-line gain from breakeven this time a year ago — and sales growth of 17.1%.

Insulet, the maker of the Omnipod 5 automated insulin delivery system, which garnered FDA clearance during the quarter, saw its EPS come in 17¢ ahead of projections on Wall Street, where analysts were looking for sales of $288.2 million.

“We are off to a great start in 2022 with first-quarter financial results that reflect strong global Omnipod adoption, consumer satisfaction and operational excellence, positioning the Company for another successful year,” Petrovic said in a news release. “The commercial launch of Omnipod 5 is progressing very well, and we are receiving excellent customer feedback. We also recently shared compelling type 2 feasibility data that demonstrates how powerful Omnipod 5 can be for this dramatically underserved population.

“Momentum across our business continues to grow, and our mission to simplify and improve the lives of people with diabetes remains at the center of everything we do.”

Insulet reaffirmed its 2022 revenue guidance for growth between 12% and 16%. The company expects Omnipod sales growth to range between 16% and 20%, raising the bottom end from a previously projected 15% increase.

PODD shares were down 3% at $220.10 per share after-hours today.

Stocks today have been hit today, as reflected by the Dow Jones Industrial Average, which was down more than 3%, more than 1,100 points, as investors reevaluated the economic effects of the Federal Reserve’s plans to combat inflation.

Despite the announcement of Petrovic’s departure as Insulet’s president and CEO, Wall Street’s outlook for the company remains positive, according to BTIG analyst Marie Thibault.

“Beyond Q1 results, we were surprised and sorry to hear that CEO Shacey Petrovic is stepping down due to medical and family reasons,” Thibault wrote in a report. “We believe Petrovic was well-respected, having led a period of strong growth and business transformation at PODD. Overall, we believe this was a robust Q1 report against a tough macroeconomic backdrop. While some may nitpick at operating margin or the measured pace of the U.S. Omnipod 5 introduction, our bullish long-term outlook remains intact.”

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Insulet

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS